Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) was up 2.7% during mid-day trading on Wednesday . The company traded as high as $410.28 and last traded at $408.89, with a volume of 463,566 shares changing hands. The stock had previously closed at $398.27.

A number of equities research analysts recently issued reports on REGN shares. Canaccord Genuity restated a “hold” rating and issued a $450.00 target price (down from $525.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, March 31st. Credit Suisse Group AG restated a “hold” rating and issued a $481.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, April 1st. Piper Jaffray Cos. restated a “hold” rating and issued a $443.00 target price on shares of Regeneron Pharmaceuticals in a report on Saturday, April 2nd. Roth Capital restated a “buy” rating and issued a $520.00 target price (down from $555.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, April 2nd. Finally, Robert W. Baird restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, April 2nd. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $506.34.

The firm has a market capitalization of $43.29 billion and a P/E ratio of 65.81. The firm’s 50 day moving average price is $367.95 and its 200 day moving average price is $391.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing the consensus estimate of $2.58 by $0.01. The company earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Regeneron Pharmaceuticals’s revenue for the quarter was up 38.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.88 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals Inc. will post $10.80 earnings per share for the current fiscal year.

In related news, major shareholder Sanofi acquired 64,731 shares of the company’s stock in a transaction on Tuesday, June 14th. The stock was purchased at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Plew Daniel P. Van sold 4,413 shares of the stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $385.77, for a total value of $1,702,403.01. Following the transaction, the executive vice president now owns 11,381 shares of the company’s stock, valued at $4,390,448.37. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently added to or reduced their stakes in REGN. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,072 shares of the biopharmaceutical company’s stock valued at $2,753,000 after buying an additional 104 shares in the last quarter. Redwood Investments LLC raised its position in Regeneron Pharmaceuticals by 9.5% in the fourth quarter. Redwood Investments LLC now owns 7,724 shares of the biopharmaceutical company’s stock valued at $4,193,000 after buying an additional 669 shares in the last quarter. Liberty Mutual Group Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 6.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 4,623 shares of the biopharmaceutical company’s stock valued at $2,510,000 after buying an additional 279 shares in the last quarter. Financial Counselors Inc. raised its position in Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock valued at $1,002,000 after buying an additional 93 shares in the last quarter. Finally, Catalyst Capital Advisors LLC raised its position in Regeneron Pharmaceuticals by 77.6% in the fourth quarter. Catalyst Capital Advisors LLC now owns 10,300 shares of the biopharmaceutical company’s stock valued at $5,592,000 after buying an additional 4,500 shares in the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.